Skip to search formSkip to main contentSkip to account menu

relacatib

Known as: N-((1S)-3-Methyl-1-((((4S,7R)-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)hexahydro-1H-azepin-4-yl)amino)carbonyl)-butyl)-1-benzofuran-2-carboxamide 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AzepinesSulfones

Narrower (1)

SB 462795

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Kathepsin-K-Inhibitoren in der Osteoporosetherapie
Zusammenfassung Kathepsin K, eine in Osteoklasten exprimierte Cysteinprotease, ist ein wichtiges Enzym in der Degradation von… 
2009
2009
Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys
The cysteine protease cathepsin K is involved in osteoclast-mediated bone resorption. We evaluated the effect of daily oral… 
Highly Cited
2006
Highly Cited
2006
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7… 
2006
2006
Relacatib : prevention and treatment of bone metastases treatment of osteoarthritis treatment of osteoporosis cathepsin k inhibitor
Cathepsin K is a cysteine protease synthesized by osteoclasts and one of the major effectors of osteoclastic bone resorption. As… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)